Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026)
Vireo Growth (VREOF) posted Cash from Financing Activities of -$4.6 million for Q1 2026, down 7.52% sequentially from -$4.3 million in Q4 2025, and down 411.11% YoY from $1.5 million in Q1 2025.
Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cash from Financing Activities for 7 years, with the latest figure at -$4.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 411.11% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (down 84.38% YoY) and the FY2025 annual result came in at $18.4 million, down 80.41% from the prior year.
- Cash from Financing Activities retreated to -$4.6 million in Q1 2026 per VREOF's latest filing, from -$4.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $93.4 million in Q4 2024 and troughed at -$9.3 million in Q2 2025.
- A 5-year average of $8.0 million and a median of $821721.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 45862.26% in 2025, down 609.87% in 2025.
- Over 5 years, Cash from Financing Activities stood at $245839.0 in 2022, then jumped by 1242.04% to $3.3 million in 2023, then surged by 2730.21% to $93.4 million in 2024, then plunged by 104.58% to -$4.3 million in 2025, then declined by 7.52% to -$4.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$4.6 million, -$4.3 million, and $32.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | 52.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.60 Mn |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | -4.28 Mn |
| Dec 31, 2025 | -4.28 Mn |
| Sep 30, 2025 | 32.90 Mn |
| Sep 30, 2025 | 32.90 Mn |
| Jun 30, 2025 | -9.30 Mn |
| Jun 30, 2025 | -9.30 Mn |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | 93.38 Mn |
| Dec 31, 2024 | 93.38 Mn |
| Sep 30, 2024 | -71,892.00 |
| Sep 30, 2024 | -71,892.00 |
| Jun 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Dec 31, 2023 | 3.30 Mn |